Correspondence 0001493152-25-002688 from Hepion Pharmaceuticals, Inc. (HEPA)

Hepion Pharmaceuticals, Inc.
Date: Jan. 17, 2025 · CIK: 0001583771 · Accession: 0001493152-25-002688

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-284052

Date

Jan. 17, 2025

Author

Not clearly detected

Form

CORRESP

Company

Hepion Pharmaceuticals, Inc.

Letter

Hepion Pharmaceuticals, Inc.

c/o Clementi Associates

Conestoga Road

Building 3, Suite 115

Rosemont, PA 19010

January 17, 2025

VIA EDGAR

United States Securities and Exchange Commission

F Street, N.E.

Washington, D.C. 20549

Attention: Jason Drory

Re: Hepion Pharmaceuticals, Inc.

Form S-1 Registration Statement, as amended

Filed December 26, 2024

File No. 333-284052

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Hepion Pharmaceuticals, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5:00 p.m., Eastern Standard Time, on Tuesday, January 21, 2025, or as soon thereafter as practicable.

Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.

HEPION PHARMACEUTICALS, INC.

By: /s/ John Brancaccio

Name: John Brancaccio

Title: Interim Chief Executive Officer

Show Raw Text

CORRESP
1
filename1.htm

Hepion
Pharmaceuticals, Inc.

c/o
Clementi Associates

919
Conestoga Road

Building
3, Suite 115

Rosemont,
PA 19010

    January
    17, 2025

VIA
EDGAR

United
States Securities and Exchange Commission

100
F Street, N.E.

Washington,
D.C. 20549

Attention:
Jason Drory

    Re:
    Hepion
    Pharmaceuticals, Inc.

    Form S-1
    Registration Statement, as amended

    Filed
    December 26, 2024

    File
    No. 333-284052

Ladies
and Gentlemen:

Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Hepion Pharmaceuticals, Inc.
(the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated
so that it will become effective at 5:00 p.m., Eastern Standard Time, on Tuesday, January 21, 2025, or as soon thereafter as practicable.

Please
notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible
as to the time the Registration Statement has been declared effective pursuant to this acceleration request.

    HEPION
    PHARMACEUTICALS, INC.

    By:
    /s/
    John Brancaccio

    Name:
    John
Brancaccio

    Title:
    Interim
    Chief Executive Officer

SecProbe.io